KR20170141463A - Micro-needles and method of mamufacture - Google Patents

Abstract

According to the present invention, a microneedle manufacturing method includes: a step of preparing a medicinal solution; and a step of forming a plurality of tips with at least one cavity through the medicinal solution. The size of the cavity is controlled by controlling the thickness of the medicinal solution covering a tip groove of a molding, a used solvent, the concentration of the medicinal solution, the viscosity of the medicinal solution, the shape of the tip groove, an evaporation temperature, an evaporation speed, and the amount of the medicinal solution. As such, the microneedle with at least one cavity is able to inject a fixed amount of medicinal solution in a very short time.

Description

[0001] MICRO-NEEDLES AND METHOD OF MAMUFACTURE [0002]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a micro needle and a method of manufacturing the same, and more particularly, to a micro needle which can efficiently administer a fixed amount of drug in a short time, and a method of manufacturing the same.

The transdermal drug delivery system has a limitation in the size of the drug molecular weight that can be delivered. Therefore, various active transdermal drug delivery systems have recently been proposed. Among them, the micro needle method of passing the keratin through the skin directly to the skin layer is receiving the most attention. In recent years, molten microneedles based on water-soluble polymers have been developed and a method has been developed in which medicines are administered at the same time that the tip penetrates into the skin.

However, since the molten microneedles are melted by body fluids after administration to the skin, they are excellent in dosage, but it takes a longer time than 30 minutes for the medicines in the tip to be completely transferred. Because of this long melting time, some of the tip portions of the microneedles administered into the skin are removed together without melting, even if the molten microneedles are removed after a predetermined dosing time.

As a result, there is a problem in that a drug contained in the tip depends on the complete melting of the tip, so that a certain amount of drug is difficult to be delivered to the skin. Therefore, in recent years, various studies for improving the dosage of the microneedle have been continuously carried out.

Japanese Patent No. 5879927 U.S. Published Patent Application No. 2014-0128811

SUMMARY OF THE INVENTION The present invention has been made in view of the above problems, and it is an object of the present invention to provide a microneedle capable of effectively administering a fixed amount of medicament and a method of manufacturing the same.

In order to accomplish the above object, a micro needle according to the present invention includes a plurality of tips formed of a drug solution that penetrates into the inside of skin and is melted, and a base for supporting the plurality of tips, Wherein at least one vacancy cavity is formed, wherein the amount of the chemical liquid, the evaporation rate, the evaporation temperature, the shape in the tip groove of the molding for producing the tip, the viscosity of the chemical liquid, the concentration of the chemical liquid, And the size of the at least one cavity is adjusted according to the thickness of the chemical solution covering the tip groove.

According to one aspect, the at least one cavity is formed in at least one of an interior of the tip, an exterior, an intermediate region of the tip, or a region deviated from the base between the tip and the base.

According to one aspect, the chemical liquid is formed by mixing a biocompatible material with purified water.

A method of manufacturing a microneedle according to a preferred embodiment of the present invention includes the steps of providing a chemical liquid and forming a plurality of tips having at least one cavity formed with the chemical liquid, At least one of the inside, the outside, the intermediate region of the tip, or the region deviated from the base between the tip and the base.

According to one aspect, the chemical liquid is formed by mixing a biocompatible material with a solvent.

According to one aspect, the biocompatible material is selected from the group consisting of hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, (PGA), polylactide-glycolidide copolymer (PLGA), hyaluronic acid (PEG), polyglycolide (PEG) Alginic acid, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, Polyanhydride, polyorthoester, polyetherester, polycaprolactone, polyesteramide, poly (butyric acid), poly (ethylene glycol) Polyacrylic acid, ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly (vinylimidazole), chlorosulfonate Polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), polyvinylpyrrolidone ), Carboxymethylcellulose, cyclodextrin, and copolymers of monomers forming such polymers and cellulose.

According to one aspect, the chemical liquid is mixed with an additive for increasing the mechanical strength, and the additive is selected from the group consisting of trehalose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melitose, dextran, sorbitol, (Lactide), poly (lactide-co-glycolide), polyanhydride, polyorthoester, polyorthoester, Polyetherester, polycaprolactone e, polyesteramide, poly (butyric acid), poly (valeric acid), polyurethane, polyacrylate, ethylene-vinyl acetate polymer, Acrylic substituted cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly (vinylimidazole), chlorosulfonate, Polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC) ), Carboxymethylcellulose, cyclodextrin, and copolymers of monomers that form such a polymer.

According to one aspect, the drug solution is mixed with an active ingredient and the active ingredient is selected from the group consisting of a protein / peptide drug, a hormone, a hormone analog, an enzyme, an enzyme inhibitor, a signal transduction protein or a part thereof, an antibody or a part thereof, A binding domain, an antigen, an attachment protein, a structural protein, a regulatory protein, a toxin protein, a cytokine, a transcription regulator, a blood coagulation factor and a vaccine.

According to one aspect, the protein / peptide medicament is selected from the group consisting of insulin, insulin sensitization factor 1 (IGF-1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), granulocyte / macrophage- stimulating factors, interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors, calcitonin, The compounds of the invention may be used in combination with other therapeutic agents such as ACTH (adrenocorticotropic hormone), TNF (tumor necrosis factor), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, Dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), gonadolerin gonadorelin, goserelin, histrelin, leuprorelin, lypressin, , Octreotide, oxytocin, pitressin, secretin, sincalide, terlipressin, thymopentin, thymosine, thymocyte, The compounds of the present invention may be used in combination with other therapeutic agents such as triptorelin, bivalirudin, carbetocin, cyclosporin, exedine, lanreotide, luteinizing hormone-releasing hormone (LHRH) nafarelin, parathyroid hormone, pramlintide, T-20 (enfuvirtide), thymalfasin and chiconotide.

According to one aspect, the solvent is selected from the group consisting of DI water, methanol, ethanol, chloroform dibutyl phthalate, dimethyl phthalate, ethyl lactate, lactic acid, glycerin, isopropyl alcohol, lactic acid, propylene glycol and the like.

According to one aspect of the present invention, the plurality of tip forming steps may include filling at least one tip of the drug solution in the tip of the molding, drying the drug solution filled in the tip groove to form the at least one cavity, And removing the molding.

According to one aspect, the drying step is performed by at least one of natural drying, vacuum drying, and pressure drying.

According to one aspect, in the drying step, the chemical liquid filled in the tip groove is cooled and solidified by a reduced pressure or a normal pressure.

According to one aspect of the present invention, the plurality of tip-forming steps may include at least one of an amount of the chemical liquid, an evaporation rate, an evaporation temperature, a shape of a tip of the molding for forming the tip, a viscosity of the chemical liquid, a concentration of the chemical liquid, And the size of the at least one cavity is adjusted according to the thickness of the chemical solution covering the tip groove.

According to the present invention having the above-described structure, first, since the cavity is formed with the microneedles, the volume of the microneedles necessary for melting can be reduced to control the dosing time.

Secondly, it is possible to supply a fixed quantity of medicine within a fixed time due to the cavity.

Third, it is possible to contribute to the improvement of the reliability of the patient due to the supply of a fixed amount of medicine.

Fourthly, the size of the cavity is controlled by adjusting the amount of the chemical liquid, the evaporation rate, the evaporation temperature, the shape of the tip tip of the molding for manufacturing the microneedle, the viscosity of the chemical liquid, the concentration of the chemical liquid, the solvent used, Thereby making it possible to cope with various medicines and dosage conditions.

Fifth, by manufacturing the microneedles with a one-stop method in which the chemical liquid is supplied to the moldings and dried, the mass production can be easily performed while being easy to manufacture.

Sixth, since the cavity can be formed of at least one of the inner and outer surfaces of the needle, the intermediate portion of the tip, or the desired portion including the base portion, etc., it is advantageous in securing diversity.

1 is a cross-sectional view schematically showing a microneedle according to a preferred embodiment of the present invention,
FIG. 2 is a cross-sectional view schematically showing a state where the micro needles shown in FIG. 1 are penetrated into the skin,
FIG. 3 is a cross-sectional view schematically illustrating various modifications of the microneedles shown in FIG. 1,
4 is a flowchart schematically showing a method of manufacturing a micro needle according to the present invention,
FIG. 5 is a flow chart schematically showing the concrete steps of the plurality of tip forming steps shown in FIG. 4,
FIG. 6 is a view sequentially showing a cavity forming operation corresponding to the microneedle manufacturing method shown in FIG. 3, and FIG.
FIG. 7 is an optical micrograph of an image of a micro needle produced by the present invention. FIG.

Hereinafter, a preferred embodiment of the present invention will be described with reference to the accompanying drawings.

Referring to FIGS. 1 and 2, a micro needle 1 according to a preferred embodiment of the present invention includes a tip 2 and a base 3.

The tip (2) comprises a plurality of tips (2) formed of a medicament that penetrates and melts into the skin (S). The tip (2) has a sharp end shape to facilitate penetration of the skin (S). In the present embodiment, the tip 2 is shown as having a substantially conical or polygonal conical shape, but it is not limited thereto. In addition, the number of the tips 2 is not limited to the illustrated example. Meanwhile, the plurality of tips 2 are each provided with a cavity, which is an empty space, and the structure of the tip 2 including the cavity 4 will be described in detail later.

The base (3) supports a plurality of tips (2). That is, the base 3 is the body of the microneedle 1 that simultaneously supports the plurality of tips 2. 2, the surface of the base 3 on which the tip 2 is provided is attachable to the skin S.

The microneedle 1 including the plurality of tips 2 and the base 3 has at least one cavity 4 as a space in which the chemical solution is emptied. At least one of the cavities 4 is formed in the shape of a mold in the tip groove 6 (see FIG. 6) of the moldings 5 (see FIG. 6) for manufacturing the micro needle 1, The size of the drug solution 7 is adjusted by adjusting the viscosity of the drug solution 7 (see FIG. 6), the concentration of the drug solution 7, the solvent used, and the thickness of the drug solution 7 covering the tip groove 6.

2, even if the base 3 is separated from the skin S, the tip 3 can be easily inserted into the skin S, (2) does not remain. As a result, a fixed amount of the chemical liquid penetrates into the skin S through the tip 2, thereby contributing to improvement in chemical liquid supplyability.

Meanwhile, in the present embodiment, the cavity 4 is formed inside the tip 2, but the present invention is not limited thereto. That is, as shown in FIG. 3A, the cavity 4 'may be formed on one side of the outer side of the plurality of tips 2, or may be formed in the cavity 4''shown in FIG. 3, the cavity 4 '''may be provided with a plurality of the tips 2 and the base 3, as shown in FIG. 3 (c) A modified example in which it is provided through is possible. Although not shown in detail, another modification is also possible in which the cavity 4 is formed to extend in the circumferential direction along the outer circumferential surface of the plurality of tips 2.

A method of manufacturing the micro needle 1 including the cavity 4 according to the present invention will be described with reference to FIG.

4 and 5, a method of manufacturing a microneedle 1 according to an embodiment of the present invention includes a chemical solution preparing step 10 and a plurality of tip forming steps 20, And the microneedles 1 are manufactured in a one-stop manner.

The chemical solution preparing step 10 prepares a chemical solution 7 (see FIG. 6) for forming the micro needle 1 (10). Here, the chemical solution (7) is a mixed solution in which a biocompatible material is mixed with a solvent. In this embodiment, the chemical solution 7 is exemplified as a 1% aqueous solution of a polymer in which a biocompatible material containing 0.01 g of hyaluronic acid is dissolved in a solvent containing 1 ml of purified water (DW) .

Wherein the biocompatible material is selected from the group consisting of hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin Carboxymethyl chitin, fibrin, agarose, pullulan polylactide, polyglycolide (PGA), polylactide-glycolidide copolymer (PLGA), hyaluronic acid, (S) selected from the group consisting of alginic acid, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, pullulan polyanhydride polyanhydride, polyorthoester, polyetherester, polycaprolactone, polyesteramide, poly (butyric acid), poly (valeric acid) ), Polyurethane, polyacrylate, ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, non-degradable polyurethane, polystyrene, polyvinyl chloride, polyvinyl fluoride, poly (vinylimidazole), chlorosulfonate polyolefin chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC) Carboxymethylcellulose, cyclodextrin, and copolymers of monomers forming such a polymer and cellulose.

The chemical solution 7 is formed by mixing a biocompatible material with an additive for increasing the mechanical strength. The additive may be selected from the group consisting of trehalose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melitose, dextran, sorbitol, xylitol, palatinite, mannitol, poly (lactide) But are not limited to, poly (glycolide), poly (lactide-co-glycolide), polyanhydride, polyorthoester, polyetherester, polycaprolactone, Polyacrylates, ethylene-vinyl acetate polymers, acrylic substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinyl chlorides, polyvinyl chlorides, Polyvinylpyrrolidone, poly (vinylimidazole), chlorosulfonate, chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), poly The aerials of monomers forming such polymers such as ethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrins, Or a combination of two or more substances selected from the group consisting of.

Further, the chemical liquid 7 is formed by mixing a biocompatible material and an active ingredient. Such active ingredients include, but are not limited to, protein / peptide drugs, hormones, hormone analogs, enzymes, enzyme inhibitors, signaling proteins or parts thereof, antibodies or portions thereof, single chain antibodies, binding proteins or binding domains thereof, , Adhesion protein, structural protein, regulatory protein, toxin protein, cytokine, transcription regulator, blood coagulation factor and vaccine. More specifically, the protein / peptide medicament may be selected from the group consisting of insulin, insulin sensitization factor 1 (IGF-1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), granulocyte / macrophage- interleukin-1, interleukin-2, EGFs (epidermal growth factors), calcitonin, interleukin-1, interleukin- , Adrenocorticotropic hormone (ACTH), tumor necrosis factor (TNF), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, , Dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), konadorerin gonadorelin, goserelin, histrelin, leuprorelin, lypress, inhaled glucocorticoid receptor antagonists, such as oxytocin, octreotide, oxytocin, pitressin, secretin, sincalide, terlipressin, thymopentin, thymosine, ), Triptorelin, bivalirudin, carbetocin, cyclosporine, exedine, lanreotide, luteinizing hormone-releasing hormone (LHRH) And includes any one of nafarelin, parathyroid hormone, pramlintide, T-20 (enfuvirtide), thymalfasin and chicotanide.

Further, the solvent of the chemical liquid (7) dissolves the biocompatible material. Such solvents include, but are not limited to, DI water, methanol, ethanol, chloroform dibutyl phthalate, dimethyl phthalate, ethyl lactate, glycerin And at least one of inorganic and organic solvents including glycerin, isopropyl alcohol, lactic acid, propylene glycol and the like.

The plurality of tip forming steps (20) form a plurality of tips (2) having at least one cavity (4) formed of a chemical liquid (7). The plurality of tip forming steps 20 will be described in more detail with reference to FIGS. 5 and 6. FIG.

5 and 6, the plurality of tip forming steps 20 may include a step 21 filling the tip groove 6 provided in the molding 5 with the chemical solution 7, A step 22 of drying the filled medicament 7 and a step 23 of removing the molding 5.

The molding 5 is provided with a plurality of tip grooves 6 corresponding to the shape of the tip 2 of the micro needle 1 as shown in FIG. After the chemical liquid 7 is supplied to the molding 5 as shown in FIG. 6 (b), the chemical liquid 7 is distributed and filled in a plurality of the tip grooves 6 as shown in FIG. 6 (c) (21).

6 (d), the chemical liquid 7 filled in the tip groove 6 is dried (22) to form at least one of the cavities 4. Then, as shown in Fig. In the drying step (22), the chemical liquid (7) filled in the plurality of tip grooves (6) is dried by evaporating moisture using at least one drying method such as natural drying, vacuum drying and pressure drying. Here, the drying to apply the pressure includes drying using an external force such as temperature, pressure, wind or the like.

In this drying step (22), as the water is evaporated, the cavity (4) is formed in the dried chemical liquid (7). For reference, in the present embodiment, the drying step 22 is repeated eight times by applying a vacuum for 10 seconds at 0.08 MPa, and then purifying the vacuum for 10 seconds by purge. Thereafter, 0.3 g of a chemical solution 7 as a mixed solution of 1% of a hyaruronic acid solution was further supplied to the molding 5, and a chemical solution 7 filled in the tip groove 6 by applying a vacuum of 600 mmHg for 10 minutes And dried. Finally, the drying step 22 is illustrated as drying the chemical solution 7 at a temperature of 70 캜 for about 40 minutes.

The drying step 22 may be a modification in which the chemical solution 7 filled in the plurality of tip grooves 6 is solidified so as to form at least one cavity 4 by cooling at a reduced pressure or a normal pressure. The solidification of the chemical liquid 7 induces moisture evaporation due to the decompression or atmospheric pressure cooling of the chemical liquid 7, thereby forming the cavity 4.

The cavity 4 formed through the drying step 22 as described above is filled with the amount of the chemical liquid 7, the evaporation rate and the evaporation temperature, the tip of the molding 5 for manufacturing the microneedles 1 (see FIG. 6) The size is adjusted according to the shape in the groove 6 (see FIG. 6), the viscosity of the chemical solution 7, the concentration of the chemical solution 7, the solvent used, and the thickness of the chemical solution 7 covering the tip groove 6.

When the cavity 4 is formed through the drying step 22, the molding 5 is removed as shown in FIG. 6E, and finally the micro needle 1 is manufactured.

An image obtained by observing the micro needle 1 produced by the above manufacturing method with an optical microscope is shown in Fig. As shown in FIG. 7, it can be seen that the cavity 4, which is a space emptied in the tip 2 of the manufactured micro needle 1, is formed.

Although the present invention has been described with reference to the preferred embodiments thereof, it will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit and scope of the invention as defined in the following claims. It can be understood that

1: Micro needle 2: Tip
3: Base 4: Cavity

Claims (15)

A plurality of tips formed of a drug solution which penetrates into the inside of the skin and melts; And
A base for supporting the plurality of tips;
/ RTI >
Wherein at least one cavity in which the chemical solution is emptied is formed in the plurality of tips, and the amount of the chemical solution, the evaporation rate, the evaporation temperature, the shape in the tip groove of the molding for producing the tip, the viscosity of the chemical solution, Wherein the size of the at least one cavity is adjusted according to a concentration of the at least one cavity, a solvent used, and a thickness of the chemical solution covering the tip groove.
The method according to claim 1,
Wherein the at least one cavity is formed in at least one of an interior of the tip, an exterior, an intermediate region of the tip, or a region deviated from the base between the tip and the base.
The method according to claim 1,
Wherein the chemical liquid is formed by mixing a biocompatible material with purified water.
Preparing a chemical liquid; And
Forming a plurality of tips each having at least one cavity with the chemical liquid;
/ RTI >
Wherein the at least one cavity is formed in at least one of an inside, an outside, an intermediate region of the tip of each of the plurality of tips, or a region deviated from the base between the tip and the base.
5. The method of claim 4,
Wherein the chemical liquid is formed by mixing a biocompatible material with a solvent.
6. The method of claim 5,
The biocompatible material may be,
But are not limited to, hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin ), Fibrin, agarose, pullulan polylactide, polyglycolide (PGA), polylactide-glycolide copolymer (PLGA), hyaluronic acid, alginic acid, , Chondroitin (sulfate), dextran (sulfate), chitosan, polylysine, collagen, gelatin, carboxymethyl chitin, fibrin, agarose, pullulan polyanhydride, But are not limited to, polyorthoesters, polyether esters, polycaprolactones, polyesteramides, poly (butyric acid), poly (valeric acid), polyurethanes, polyacrylates, But are not limited to, ethylene-vinyl acetate polymers, acrylic substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinylchlorides, polyvinyl fluorides, poly (vinylimidazoles), chlorosulphonate polyolefins, Polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin, A method of producing a micro needle comprising at least one selected from the group consisting of a copolymer of monomers forming such a polymer and a cellulose
6. The method of claim 5,
The chemical liquid is mixed with an additive for increasing the mechanical strength,
The additive may be selected from the group consisting of trehalose, glucose, maltose, lactose, lactulose, fructose, turanose, melitose, melitose, dextran, sorbitol, xylitol, palatinite, mannitol, poly (lactide) But are not limited to, poly (glycolide), poly (lactide-co-glycolide), polyanhydride, polyorthoester, polyetherester, polycaprolactone, Polyacrylates, ethylene-vinyl acetate polymers, acrylic substituted cellulose acetates, non-degradable polyurethanes, polystyrenes, polyvinyl chlorides, polyvinyl chlorides, Polyvinylpyrrolidone, poly (vinylimidazole), chlorosulfonate, chlorosulphonate polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), poly The aerials of monomers forming such polymers such as ethylene glycol (PEG), polymethacrylate, hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrins, Wherein the microneedles are made of one or two or more substances selected from the group consisting of a combination of two or more substances.
6. The method of claim 5,
The drug solution is mixed with active ingredients,
The active ingredient may be a protein / peptide drug, a hormone, a hormone analog, an enzyme, an enzyme inhibitor, a signal transduction protein or a part thereof, an antibody or a part thereof, a single chain antibody, a binding protein or a binding domain thereof, A protein, a toxin protein, a cytokine, a transcription regulator, a blood coagulation factor, and a vaccine.
9. The method of claim 8,
The protein / peptide medicament may be selected from the group consisting of insulin, IGF-1 (insulin sensitivity factor 1), growth hormone, erythropoietin, granulocyte-colony stimulating factors (G-CSFs), granulocyte / macrophage- Interferon alpha, interferon beta, interferon gamma, interleukin-1 alpha and beta, interleukin-3, interleukin-4, interleukin-6, interleukin-2, epidermal growth factors, calcitonin, adrenocorticotropic hormone ), TNF (tumor necrosis factor), atobisban, buserelin, cetrorelix, deslorelin, desmopressin, dinorpin A dynorphin A (1-13), elcatonin, eleidosin, eptifibatide, growth hormone releasing hormone-II (GHRH-II), gonadorelin, Goserelin, histrelin, leuprorelin, lypressin, octreotide, the compounds of the present invention may be selected from the group consisting of octreotide, oxytocin, pitressin, secretin, sincalide, terlipressin, thymopentin, thymosine, a triptorelin, a bivalirudin, a carbetocin, a cyclosporin, an exedine, a lanreotide, a luteinizing hormone-releasing hormone (LHRH), a nafarelin, A method for producing a micro needle comprising at least one of a hormone, pramlintide, T-20 (enfuvirtide), thymalfasin and chicotanide.
6. The method of claim 5,
The solvent may be selected from the group consisting of DI water, methanol, ethanol, chloroform dibutyl phthalate, dimethyl phthalate, ethyl lactate, glycerin An organic solvent such as glycerin, isopropyl alcohol, lactic acid, propylene glycol and the like.
5. The method of claim 4,
Wherein the plurality of tip forming steps comprise:
Filling the at least one tip groove provided in the molding with the chemical solution;
Drying the drug solution filled in the tip groove to form the at least one cavity; And
Removing the molding;
≪ / RTI >
12. The method of claim 11,
Wherein the drying step is performed by at least one of natural drying, vacuum drying, and pressure drying.
12. The method of claim 11,
Wherein the drying step comprises cooling the drug solution filled in the tip groove at a reduced pressure or an atmospheric pressure to solidify the drug solution.
5. The method of claim 4,
Wherein the plurality of tip forming steps include a step of forming a plurality of tips, an amount of the chemical liquid, an evaporation rate, an evaporation temperature, a shape of a tip of the molding for forming the tip, a viscosity of the chemical liquid, a concentration of the chemical liquid, Wherein the size of the at least one cavity is adjusted according to the thickness of the covering liquid.
A microneedle fabricated by the microneedle manufacturing method according to any one of claims 4 to 14.

Images